exRNAdisease

General Information

Database ID:

exR0088000

RNA Name:

hsa-miR-301a-3p

RNA Type:

miRNA

Chromosome:

chr17

Starnd:

Coordinate:

Start Site(bp):

59151149

End Site(bp):

59151171

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ALDH3A2	chr17	19648136	19685760	+
TNFRSF1B	chr1	12166991	12209228	+
CAMTA1	chr1	6785454	7769706	+
CPEB4	chr5	173888349	173961980	+
ZDHHC7	chr16	84974181	85011535	-
STARD13	chr13	33103137	33350630	-
APCDD1	chr18	10454635	10489949	+
HABP4	chr9	96450169	96491336	+
TBC1D5	chr3	17157162	18444817	-
ZNF12	chr7	6688433	6706947	-
PTEN	chr10	87863625	87971930	+
NPTX1	chr17	80466834	80477843	-
APOL6	chr22	35648446	35668404	+
CD151	chr11	832887	839831	+
PPP1R9A	chr7	94907202	95296415	+
KIAA0232	chr4	6781375	6884170	+
ZNF594	chr17	5179535	5191868	-
LIPA	chr10	89213569	89414557	-
LYSMD2	chr15	51723011	51751585	-
MLPH	chr2	237485428	237555322	+
EMP1	chr12	13196723	13219941	+
KLF4	chr9	107484852	107490482	-
RTN4	chr2	54972187	55112621	-
SCAF11	chr12	45919131	45992120	-
RNF11	chr1	51236273	51273447	+
XXYLT1	chr3	195068284	195271159	-
SHANK2	chr11	70467856	71252577	-
NSD2	chr4	1871393	1982207	+
SLC7A5	chr16	87830023	87869507	-
MTMR9	chr8	11284816	11328146	+

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000591	chr15	41961025	41962156	+
hsa_circ_0001454	chr4	154524454	154533552	+
hsa_circ_0000384	chr12	27867712	27877119	+
hsa_circ_0001723	chr7	91924202	91948826	+
hsa_circ_0000892	chr19	11941431	12014514	+
hsa_circ_0001605	chr6	42903447	42905047	+
hsa_circ_0000155	chr1	168007608	168014465	+
hsa_circ_0001495	chr5	68470703	68471364	+
hsa_circ_0000943	chr19	47421744	47440665	+
hsa_circ_0000018	chr1	15860731	15863309	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC011503.2	chr19	23927788	23929287	+
AC021092.1	chr19	44103007	44113183	-
AC135050.6	chr16	31122235	31124064	+
AC234582.1	chr1	155195004	155205495	+
AL031595.3	chr22	44139365	44153626	+
AL049840.4	chr14	103694516	103695050	-
AL158206.1	chr9	19453209	19455173	+
AL158825.2	chr9	75009828	75016036	-
AL603839.3	chr1	40493157	40508661	-
CKMT2-AS1	chr5	81201341	81301565	-
H19	chr11	1995176	2001470	-
HAGLR	chr2	176164051	176188958	-
KCNQ1OT1	chr11	2608328	2699994	-
LINC01089	chr12	121795267	121803906	-
MIR17HG	chr13	91347820	91354579	+
NEAT1	chr11	65422774	65445540	+
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.